Latest Industry Insights

Discover how scalable, human-based in vitro models are reshaping discovery pipelines, balancing complexity with reproducibility, and enabling new kinds of experimentation that go beyond the limits of animal research.

Dr. Jamie Spangler gives a vision of how engineered proteins could overcome the toughest challenges in cancer immunotherapy.

An epigenetic analysis platform spun out of academia could address current issues with wider adoption of epigenetic profiling as a cancer diagnostic tool. Hear about the challenges, successes and importance of industry partners.

Discover insights on the challenges of CTCs and ctDNA from liquid biopsies as cancer diagnostic tools, how novel technology is helping to overcome some of these issues and the future monitoring landscape.

From theory to clinic, explore how molecular glue innovation is transforming targeted protein degradation for cancer and other diseases. Offering a new path to degrade targets once thought undruggable.

In this interview, discover how Astoriom's Integrated Stability & Sustainability Outsourcing Model addresses traditional storage challenges and enables biopharma companies to respond more nimbly to disruptions.

In this conversation, Joe Day speaks about the most exciting developments in AI-powered cancer research, the critical importance of diverse, high-quality data and what it takes to build patient trust.

Today, single-cell technologies are not only dissecting genomic, transcriptomic and proteomic profiles but also enabling dynamic measurements of cellular functions. Bruker's new Beacon Discovery Platform could make this a reality for more labs.

In this interview, Technology Networks spoke with Kara Egan, CEO and co-founder of Teal Health, to learn more about how they are reshaping cervical cancer prevention.

James Connelly discusses the importance of third-party verification and how recent funding will help accelerate the development of Impact Laboratories' digital sustainability tools.